MicroRNAs (miRNAs) are critical regulators of gene expression. These small, non-coding RNAs are believed to regulate more than one third of protein-coding genes, and have been implicated in the control of many biological processes, including the biology of glioma. The functional significance in some of the miRNAs begins to emerge. This paper reviews the biogenesis of miRNAs, their roles in neuronal development and tumorigenesis of gliomas, and their contribution as tumor biomarkers. Research in this area is quickly gathering pace and is illuminating important aspects of the diseases that may ultimately lead to novel therapeutic interventions, as well as diagnostic and prognostic tools for brain tumors.

Background Many surgical techniques are used to improve the postoperative visual acuity for rhegmatogenous retinal detachment(RRD)during recent decade,and scleral buckling surgery is one of these operations.Whether the visual function after operation can be rescued is an important issue. Objective The aim of this study was to analyze the risk factors of influencing the postoperative vision following scleral buckling surgery for primary macula-off RRD. Methods The clinical and follow-up data from consecutive series of 116 eyes of 116 patients received scleral buckling surgery for primary maeula-off RRD were retrospectively reviewed.The relationship of multiple factors,including age,preoperative best corrected visual acuity(BCVA),duration of disease,refractive error,location of retinal hole,number of retinal hole,area and height of retina detachment,management of subretinal fluid and intravitreal gas injection,with visual acuity were analyzed respectively by χ2 test.The correlations among statistically significant factors with postoperative vision were analyzed by multivariate Logistic regression analysis.Written informed consent was obtained from any patient before surgery. Results The postoperative vision outcome was found with significantly difference among different preoperative vision groups(P=0.002)and different course (P=0.009).There were significant differences between the groups with different preoperative BCVA(P=0.002)and duration of disease(P=0.009).Multivariate Logistic regression analysis showed that the preoperative BCVA was the only variable affecting postoperative visual result(r=0.400,P=0.009).Considerable linear correlation wag seen between preoperative vision and postoperative vision(r= 0.400,P=0.000).The probability with postoperative vision of t>0.4 in the eyes with preoperative≥0.05 was 3 folds more than that of preoperative<0.05(OR=2.992).The better visual outcome after scleral buckling surgery was seen in the eyes with the course≤7 days. Conclusion Preoperative BCVA and duration of disease are the key factors associated with the postoperative BCVA.Scleral buckling surgery should be performed within the first week for primary macula-off RRD.

Induced pluripotent stem (iPS) cell based on recently developed stem cell reprogramming technique holds great hope for regenerative medicine,in vitro disease modeling and drug evaluation.Recent progress on clinical hematology includes in vitro generation of hematopoietic progenitors and mature blood cells from somatic cells,iPS cells derived from chronic myeloid leukemia cells for the better understanding of the resistance mechanisms of bcr-abl inhibitor imatinib,and moreover,correction the monogenic inherited disease using gene-targeted strategies.However,whether the iPS cells can fully replace human embryonic stem cells still needs further investigation.

Genomic diseases caused by pathogenic copy number variations (pCNVs) are a group of important causes for birth defects. At present, the methods used to detect CNV mainly include chromosomal microarray analysis (CMA) and copy number variation sequencing (CNV-seq) based on next generation sequencing (NGS). In recent years, CNV detection technology has been widely used in the field of prenatal diagnosis. To standardize the clinical application of such technologies, the authors have formulated a guideline for the application of CNV testing in prenatal diagnosis, which includes the basic requirement, scope of application, clinical testing and consultation, procedure of CNV analysis in prenatal diagnosis, with an aim to better serve the patients.

OBJECTIVE: To explore pharmacokinetics and relative bioavailability of penehyclidine hydrochloride in healthy subjects. METHODS: This study was an open, randomized and cross-over trial design. Twelve healthy subjects were randomized to receive pharmacokinetic analysis which were performed according to the order of ABC, BCA and CAB, and then pharmacokinetic trial of multiple dose was performed following penehyclidine hydrochloride. Twenty healthy subjects were selected to receive bioavailability study following an order of BD or DB. Blood and urine samples were collected at prescribed time and then investigated by LC-MS/MS. RESULTS: The 11 of 12 cases finished the pharmacokinetic trial. The lineare ranges of penehyclidine hydrochloride in plasma and urine were 0.1-8 ng·mL-1, 1-100 ng·mL-1, respectively and accuracy of the method was within 85%-115%. The concentration-time curve of penehyclidine hydrochloride was dose dependent within the ranges of 0.4-0.8 mg after oral administration. ρmax and AUC were significantly increased (P<0.01), Vd and CL were significantly decreased (P<0.01) following multiple dose. The relative bioavailability of penehyclidine hydrochloride was (72.44±21.03)%. The average cumulative excretion rate of penehyclidine hydrochloride with original form accounted for (4.98±1.10)% of the total administered dose. CONCLUSION: The characteristic of linear pharmacokinetics of penehyclidine hydrochloride is performed in healthy subjects after oral administration. Its excretion is mostly via non-urinary system or other metabolites.

Objective: To investigate the relationship between prognosis of patients with primary clear cell renal cell carcinoma (ccRCC) after radical nephrectomy and expression of tumor metastasis-associated gene CD99 and to analyze the prognostic factors of ccRCC paiients. Methods: Semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) was used to examine the expression of CD99 in primary ccRCC tissues and their corresponding adjacent tissues. The prognosis and risk factors of survival time of patients were studied by follow-up investigation, and the main risk factors were screened by Cox hazard regression model. Results: Compared with the adjacent renal tissues, 73.5% ccRCC tissues had up-regulated CD99 expression, with significant difference found between the two groups (P=0.000). Cox hazard regression model showed that high CD99 expression in ccRCC tissues was not a survival risk factor of ccRCC patients after radical nephrectomy (HR=0.14, 95%CI[0.01, 2.15]); and age (HR=1.18, 95%CI[1.01, 1.38]), TNM stages (HR=51.91, 95%CI[4.31, 625.87]), diabetes (HR=59.94, 95%CI[2.21, 1 627]) and hypertension (HR=47.72, 95%CI[1.37, 1 670]) were the major risk factors for the survival of patients after radical nephrectomy. The 1-year and 2-year survival rates of ccRCC patients in TNM stage I were significantly higher than those in TNM stage II-IV, respectively (100.0% vs 60.0%, P=0.004; 93.8% vs 8.3%,P=0.000). Conclusion: The expression of tumor metastasis-related gene CD99 may not be associated with the prognoses of ccRCC patients. Age, TNM stage, diabetes and hypertension are the major risk factors of prognosis after resection of ccRCC.

Objective: To predict the B cell epitopes of tumor-associated protein EIF4G1 subtypes. Methods: The sequences of all the protein subtypes of EIF4G1 were retrieved from NCBI protein database. Based on single parameter evaluation, including hydrophilicity, flexility, antigenicity, the B cell epitopes of the EIF4G1 protein subtypes were predicted using NPS@ structure software and ABCpred software. Results: EIF4G1 protein had five subtypes. The variation of the five different EIF4G1 subtypes was limited within a 300aa region. We identified eight epitopes locating in or near 14-19, 21-27, 52-61, 106-112, 113-139, 183-189, 201-216, and 217-224, which can be used to identify specific B cell epitopes of different protein subtypes. Conclusion: B cell epitopes of EIF4G1 protein subtypes do exist, and they may be used for the protein subtypes evaluation and early diagnosis of tumor patients using artificially-produced matched peptides.

With development of bio-technique, more and more proteins were applied as clinical approaches. However, the protein homogeneity, especially the N-glycosylation limited the further research and application of these protein drugs. The analysis method for N-glycans is believed to be critical in protein drugs development. To enhance the N-glycans isolation efficiency and accelerate the pretreatment, a new strategy was built on ultrafiltration-devices. New methods increased the isolation efficiency of N-glycans containing N-acetylglucosa mine with 10%-20%. The degrading of N-glycans containing sialic acids was also minimized with this method. 20%-100% more N-glycans with sialic acids were isolated. The pretreatment was finished within 30 min. Coupled with HPLC-HRMS, an effective and reliable strategy designed for protein drugs N-glycans analysis were developed.
Glycoproteins ; chemistry ; Glycosylation ; Polysaccharides ; chemistry ; Ultrafiltration ; instrumentation

Objective To investigate the application value of apolipoprotein E (ApoE) genotyping by DNA microarray technology and the relationship between ApoE allelic frequency and serum ApoE levels in both healthy individuals and patients with Alzheimer ′s disease (AD).Methods This research is case-control study.DNA microarray was used to detect the ApoE genotypes of AD patients (n =280) and age-matched non-demented elderly control subjects ( n =230) .The cases and controls were collected in Guangzhou Huiai Hospital during July 2014 to September 2015.The accuracy of genotype results was verified by DNA sequencing.Serum ApoE levels were measured by immunoturbidimetric assay .The ApoE genotype distribution and the relationship between ApoE allelic frequency and serum ApoE levels were analyzed.The “t” test was used to compare the ApoE levels of AD patients and controls , variance analysis was used to analyze ApoE levels in the persons with different genotype .Results DNA microarray technology genotyping results were completely consistent with the results of DNA sequencing .In AD group, the ApoE genotype distribution were 2.9%(8 /280) for ε2ε3, 1.8% (5/280) for ε2ε4, 46.8% (131/280)for ε3ε3,45.4%(127 /280) for ε3ε4 and 3.1%(9 /280) for ε4ε4.While in the control group, the ApoE genotype distribution were 0.9%(2 /230) for ε2ε2, 12.6% (29/230)for ε2ε3, 1.3%(3 /230) forε2ε4, 70.0% (161 /230) for ε3ε3 and 15.2% (35 /230) for ε3ε4.The average serum concentrations of ApoE were (33.29 ±10.87)mg/L in AD patients and (41.28 ±10.95)mg/L in the controls.Among all participants, the average serum levels of ApoE were (50.86 ±6.21) mg/L for ε2 carriers, (38.78 ± 12.07)mg/L for ε3 carriers and (30.47 ±7.68)mg/L for ε4 carriers.In AD group,ApoE level of ε2, ε3,ε4 carriers is (50.31 ±9.08)mg/L, (38.30 ±7.60) mg/L and (32.86 ±5.93)mg/L respectively.In the control group, the ApoE level of ε2, ε3, ε4 carriers is (51.00 ±5.53)mg/L, (41.01 ±10.09)mg/L and (32.86 ±5.93)mg/L respectively.The ApoE levels of persons with different ApoE alleles are ε2 >ε3 >ε4. The difference is significant (F =89.6, P <0.05).However, the ApoE levels in persons with the same ApoE genotype between healthy individuals and AD patients have no significant difference ( t =0.981, 2.878 and 1.732 respectively, P >0.05) .Conclusions DNA microarray technology possesses high efficiency and favorable accuracy.The ε2 allele is associated with a higher ApoE concentration , ε3 allele with a mediate concentration and ε4 allele with a lowest concentration.Serum concentrations of ApoE showed no significant difference between AD patients and the healthy groups who have the same genotype .The primary cause of the low serum ApoE levels in AD patients is that the ApoE ε4 allelic frequencies of them are higher than that of the healthy persons.

Objective To investigate the effects of sodium arsenite (NaAsO2) on cell survival circumstance,reactive oxygen species (ROS) and cell apoptosis in human normal hepatic cells (L-02).Methods L-02 cells were exposed to different doses of NaAsO2 (0,50,100,150 μmol/L) for 24 h.MTT assay was used to detect the survival of L-02 cells,and flow cytometry (FCM) was used to detect the ROS levels and the early (Q4),late (Q2) apoptosis of L-02 cells.Results Cell survival rate:cell survival rate was compared between groups,the difference was statistically significant (F =350.51,P ＜ 0.05),the cell survival rates of 50,100 and 150 μmol/L NaAsO2 groups [(87.30 ± 3.74)％,(49.03 ± 4.72)％,(13.44 ± 4.01)％] were significantly lower than that of the control group [(100.00 ± 0.00)％,all P ＜ 0.05];compared with 50 μmol/L NaAsO2 group,the cell survival rates of 100 and 150 μmol/L NaAsO2 groups were significantly decreased (all P ＜ 0.05);compared with 100 μmol/L NaAsO2 group,the cell survival rate of 150 μmol/L NaAsO2 group was significantly decreased (P ＜ 0.05).The ROS levels:ROS levels were compared between groups,the difference was statistically significant (F =407.78,P ＜ 0.05),the ROS levels of 100 and 150 μ mol/L NaAsO2 groups (3 212.00 ± 221.93,5 521.33 ± 179.63) were significantly higher than that of the control group (1 691.67 ± 73.98,all P＜ 0.05);compared with 50 μmol/L NaAsO2 group (1 927.67 ± 62.45),the ROS levels of 100 and 150 μmol/L NaAsO2 groups were significantly increased (all P ＜ 0.05);compared with 100 μmol/L NaAsO2 group,the ROS level of 150 μ mol/L NaAsO2 group was significantly increased (P ＜ 0.05).Cell apoptosis:cell apoptosis rates of Q2,Q4 and Q2 + Q4 were compared between groups,the differences were statistically significant (F =256.84,26.53,63.89,all P ＜ 0.05);excecpt the cell apoptosis rate of Q4 in 50 μ mol/L NaAsO2 group [(5.43 ± 0.57) ％],the cell apoptosis rates of Q2 [(5.67 ± 0.21)％] and Q2 + Q4 [(11.10 ± 0.40) ％] in 50 μ mol/L NaAsO2 group,the cell apoptosis rates of Q2 [(13.60 ± 0.79) ％],Q4 [(7.37 ± 2.01) ％] and Q2 + Q4 [(20.97 ± 2.38) ％] in 100 μmol/L NaAsO2 group,the cell apoptosis rate of Q2 [(13.47 ± 0.78) ％],Q4 [(16.97 ± 3.45) ％] and Q2 + Q4 [(30.43 ± 3.84) ％] in 150 μmol/L NaAsO2 group were significantly higher than those of the control group [Q2:(3.47 ± 0.12) ％,Q4:(2.90 ± 0.90) ％,Q2 + Q4:(6.37 ± 1.00) ％,all P ＜ 0.05];compared with 50 μmol/L NaAsO2 group,the cell apoptosis rates of Q2,Q4 and Q2 + Q4 in 100 and 150 μmol/L NaAsO2 groups were increased,except the cell apoptosis rate of Q4 in 100 μ mol/L NaAsO2 group,the differences were statistically significant (all P＜0.05);the cell apoptosis rates of Q4 and Q2 + Q4 in 150 μmol/L NaAsO2 group compared with 100 μmol/L NaAsO2 group were significantly increased (all P ＜ 0.05).Conclusions NaAsO2 can induce L-02 cells to increase ROS levels,and inhibit L-02 cell proliferation.In addition,NaAsO2 can induce early apoptosis and late apoptosis in L-02 cells.